Brain endothelial dysfunction is a phenomenon that occurs in many neurodegenerative diseases. Neurodegeneration is a progressive process and no treatment available today can stop it, highlighting the high unmet medical need. Using microRNAs as therapeutic tools, Brendinn Therapeutics aims to develop a neuroprotective strategy, based on improving brain endothelial function, which may have potential in different therapeutic areas such as:
Multiple Sclerosis (MS): MS is a chronic neurodegenerative disease that affects a relatively young population. Although medication is usually effective in the early phases of disease, no medication is available that stops disease progression. Brain endothelial dysfunction plays a significant role in the pathology of the disease, and blood vessel leakage can be visualized using MRI imaging. Brendinn Therapeutics believes that long term endothelial dysfunction is a driving force behind the persistent neurodegeneration that is observed in MS and is dedicated to stopping or slowing this process by restoring brain endothelial function using microRNAs. Being a spin-out from the MS center Amsterdam, Brendinn Therapeutics has ample access to state of the art knowledge, samples and patients.
Amyotrophic Lateral Sclerosis (ALS): ALS is an aggressive neurodegenerative disease that mainly affects motor neurons in the brain and spinal cord. Brain and spinal cord endothelial dysfunction is observed early in ALS pathology and has been shown both in tissue derived from patients and from the most commonly used animal models.
Traumatic brain injury (TBI): TBI is the result from a severe external insult to the central nervous system. This trauma not only causes imminent damage, but also initiates a cascade of events in the CNS that leads to inflammatory responses, brain endothelial dysfunction and subsequent secondary damage.
Stroke: Stroke not only causes acute damage to the brain endothelium due to shortage of glucose and oxygen, but also induces long term endothelial dysfunction as a secondary effect. Restoring brain endothelial function may limit secondary damage and improve recovery.
Vascular dementia: After Alzheimer’s Disease (AD), vascular dementia is the second most common type of dementia. Although AD (which is associated with Amyloid β deposits) and vascular dementia (associated with brain endothelial dysfunction) are considered different types of dementia, they co-exist in most demented patients and may exhibit significant interplay.
Parkinson’s Disease (PD): In Parkinson’s disease, the dopaminergic neurons from the substantia nigra in the midbrain are affected. Like many other neurodegenerative diseases the exact cause is unknown, but it has been shown that waste efflux by brain endothelial cell is reduced and neuroinflammation occurs. Therefore, restoring brain endothelial function may also be beneficial in treating Parkinson’s disease